All In Biotech

Drug Trial Radar · NCT03250338

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Aug 16, 2018

Primary completion

Apr 3, 2026

Study completion Apr 3, 2026

Sponsor

Lead sponsor
Arog Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Interventions

  • CrenolanibDrug

    Crenolanib will be administered orally

  • CytarabineDrug

    HAM regimen FLAG-Ida

  • MitoxantroneDrug

    HAM regimen

  • Placebo Oral TabletDrug

    Placebo will be administered orally

  • FludarabineDrug

    FLAG-Ida regimen

  • IdarubicinDrug

    FLAG-Ida regimen

  • G-CSFDrug

    FLAG-Ida regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: 3 years

Locations

62 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Sacramento, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • University of Florida

    Gainesville, Florida

  • University of Chicago

    Chicago, Illinois

  • Kansas University

    Kansas City, Kansas

  • Karmanos Cancer Center

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Alberta

    Edmonton, Alberta, Canada

  • Hospital Avicenne

    Bobigny, France

  • CHU Grenoble Alpes

    Grenoble, France

  • Hospital Center of Versailles (Le Chesnay)

    Le Chesnay, France

  • Hospital Claude Huriez - Chru Lille

    Lille, France

  • Institut Paoli-Calmettes

    Marseille, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • University Hospital Nice L'Archet

    Nice, France

  • Hôpital St Louis

    Paris, France

  • CHU de Bordeaux

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU de Poitiers

    Poitiers, France

  • Institut Universitaire du Cancer Toulouse

    Toulouse, France

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • Technische Universität Dresden

    Dresden, Germany

  • Universitätsklinikum Essen (AöR)

    Essen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • AOU Policlinico Sant'Orsola-Malpighi

    Bologna, Italy

  • ASST Spedali Civili di Brescia

    Brescia, Italy

  • AOU Careggi

    Florence, Italy

  • IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy

  • IRCCS San Raffaele Hospital

    Milan, Italy

  • IRCCS Foundation Ca 'Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Aorn Antonio Cardarelli

    Naples, Italy

  • AOU Federico II

    Naples, Italy

  • AOU Maggiore della Carità

    Novara, Italy

  • AO Ospedali Riuniti Villa Sofia-Cervello

    Palermo, Italy

  • AO Ospedali Riuniti Marche Nord

    Pesaro, Italy

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.